Serum levels of Matrix Metalloproteinases (MMPs) in patients undergoing endovascular intervention for peripheral arterial disease.

[1]  Jun Fan,et al.  Distribution and Dynamic Changes in Matrix Metalloproteinase (MMP)-2, MMP-9, and Collagen in an In Stent Restenosis Process. , 2021, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[2]  R. Serra,et al.  Different inflammatory cytokines release after open and endovascular reconstructions influences wound healing , 2019, International wound journal.

[3]  R. Serra,et al.  Inflammatory biomarkers, vascular procedures of lower limbs, and wound healing , 2019, International wound journal.

[4]  Hilary Graham,et al.  The genesis and evolution of bead-based multiplexing. , 2019, Methods.

[5]  J. Lantos,et al.  Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA) , 2018, BMC Neurology.

[6]  G. Santulli,et al.  Update on peripheral artery disease: Epidemiology and evidence-based facts. , 2018, Atherosclerosis.

[7]  Jeroen J. Bax,et al.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[8]  Jason L Johnson,et al.  Metalloproteinases in atherosclerosis , 2017, European journal of pharmacology.

[9]  I. Sagi,et al.  Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. , 2017, Biochimica et biophysica acta. Molecular cell research.

[10]  A. Spathis,et al.  The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease. , 2017, Annals of vascular surgery.

[11]  S. George,et al.  Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis. , 2017, Progress in molecular biology and translational science.

[12]  S. Spiliopoulos,et al.  Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[13]  S. Gangemi,et al.  Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia , 2016, International wound journal.

[14]  N. Papo,et al.  Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine , 2016 .

[15]  Jeffrey A. Jones,et al.  Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability , 2016, Journal of Vascular Research.

[16]  S. Tyagi,et al.  Regulation and involvement of matrix metalloproteinases in vascular diseases. , 2016, Frontiers in bioscience.

[17]  N. Kucher,et al.  Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[18]  Jun-peng Liu,et al.  Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting , 2015, Neural regeneration research.

[19]  M Hassan Murad,et al.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.

[20]  S. Tyagi,et al.  Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms , 2015, Vascular health and risk management.

[21]  Ya Li Correlation analysis of levels of adiponectin and matrix metalloproteinase-9 with stability of coronary heart disease. , 2015, Technology and Health Care.

[22]  R. Vandenbroucke,et al.  Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.

[23]  K. Santos,et al.  Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[24]  A. AbuRahma,et al.  C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. , 2013, Journal of vascular surgery.

[25]  M. Libra,et al.  Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. , 2012, Cytokine.

[26]  M. Leinonen,et al.  Elevated MMP‐8 and Decreased Myeloperoxidase Concentrations Associate Significantly with the Risk for Peripheral Atherosclerosis Disease and Abdominal Aortic Aneurysm 1 , 2010, Scandinavian journal of immunology.

[27]  E. Boerwinkle,et al.  Association of Circulating Matrix Metalloproteinases With Carotid Artery Characteristics: The Atherosclerosis Risk in Communities Carotid MRI Study , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Jason L Johnson,et al.  MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis , 2010, Cardiovascular research.

[29]  M. Serio,et al.  Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. , 2008, International journal of cardiology.

[30]  Jason L. Johnson,et al.  Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability , 2007, Expert review of cardiovascular therapy.

[31]  John V. White,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[32]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[33]  J. Sluijter,et al.  Vascular Remodeling and Protease Inhibition—bench to Bedside , 2022 .

[34]  Giuseppe Pennisi,et al.  Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease , 2005, Vascular medicine.

[35]  G. Lip,et al.  Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity , 2005, Journal of internal medicine.

[36]  T. Ludwig,et al.  Microtubule-Dependent Matrix Metalloproteinase-2/Matrix Metalloproteinase-9 Exocytosis , 2004, Cancer Research.

[37]  J. Álvarez-Sabín,et al.  Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. , 2004, Journal of vascular surgery.

[38]  J. Plutzky The vascular biology of atherosclerosis. , 2003, The American journal of medicine.

[39]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[40]  U. Ikeda,et al.  Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. , 2002, Atherosclerosis.

[41]  G. Cherr,et al.  Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  G. Pasterkamp,et al.  Oral Matrix Metalloproteinase Inhibition and Arterial Remodeling After Balloon Dilation: An Intravascular Ultrasound Study in the Pig , 2001, Circulation.

[43]  G Pasterkamp,et al.  Arterial Remodeling: Mechanisms and Clinical Implications , 2000 .

[44]  J. Verheijen,et al.  Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon , 2000 .

[45]  J. Woessner,et al.  Matrix Metalloproteinases* , 1999, The Journal of Biological Chemistry.

[46]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.